Skip to main content

trametinib (Mekinist®)

 

Status: In progress

For the off-label treatment of recurrent low grade serous ovarian carcinoma (LGSOC) which has progressed following at least 1 previous platinum-based regimen.

Medicine details

Medicine name trametinib (Mekinist®)
Formulation 2 mg film-coated tablets
Reference number OW30
Indication

As above

Company Novartis Pharmaceuticals UK Ltd
BNF chapter Malignant disease & immunosuppression
Submission type One Wales
Status In progress
Scrutiny Panel meeting date 06/02/2025
OWMAG meeting date 12/05/2025
AWMSG meeting date 18/06/2025
Follow AWTTC: